Adults prescribed a GLP-1 agent had a 12% higher risk for developing a new chronic cough -- one that persists for over 8 ...

THERE is a long list of things that might give you a cough at this time of year – and a new discovery has made a surprising ...

The number of women seeking permanent birth control — via tubal ligation — has increased more than 50% following the Supreme ...

In this age of booming social media, wellness trends are everywhere. Some vanish overnight, while others surprise us by ...

A new study finds popular GLP-1 medications for weight loss and diabetes may increase the risk of developing chronic cough. A ...

Imfinzi in combination with standard-of-care FLOT chemotherapy has been approved in the U.S. for the treatment of adult ...

With up to 20 per cent of UK adults living with recurring symptoms, these are the potential causes and the measures to get it ...

The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...

Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

The FDA has approved AstraZeneca’s IMFINZI combined with standard FLOT chemotherapy for adults with resectable, early-stage ...

The US FDA has approved a durvalumab (Imfinzi, AstraZeneca)-based regimen for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Specifically, durvalumab, an ...